Drug Profile
Research programme: submicron respiratory disease therapeutics - iCeutica
Alternative Names: ICE-1202; ICE-1203; ICE-1204Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator iCeutica
- Class
- Mechanism of Action Cholinergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Hypersensitivity
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Allergy in USA (Inhalation)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation)